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The effect of palonosetron on postoperative nausea and
vomiting in supratentorial craniotomy patients
Halit MADENOĞLU, Cihan AKDEMİR, Recep AKSU, Cihangir BİÇER, Ayşe ÜLGEY, Adem BOYACI

Aim: Postoperative nausea and vomiting (PONV) is a condition that adversely affects postoperative patient comfort.
Supratentorial craniotomy patients were therefore monitored to establish the therapeutic efficiency of 2 different doses
of palonosetron.
Materials and methods: Patients scheduled for elective supratentorial craniotomy were randomly assigned to 3 groups:
a control group (n = 30), a 0.05 mg palonosetron group (n = 30), and a 0.075 mg palonosetron group (n = 30). The drugs
were given intravenously at the commencement of dura mater closure. Anesthesia maintenance was provided with 1
MAC sevoflurane in a 50% air and O2 mixture. After the extubation, the patients were monitored for 72 h with respect
to postoperative nausea and vomiting.
Results: In the first 6 h, nausea was significantly lower in the 0.075 mg palonosetron group compared to the control
group (P = 0.019). The incidences of nausea, retching, and vomiting at 0–72 h postoperatively were significantly lower
in the 0.075 mg palonosetron group than in the 0.05 mg palonosetron or saline groups (P < 0.001).
Conclusion: In supratentorial craniotomy cases, PONV was reduced more effectively in the 0.075 mg palonosetron
group than in the 0.05 mg palonosetron and control groups.
Key words: Supratentorial craniotomy, postoperative nausea and vomiting, palonosetron

Introduction
Postoperative nausea and vomiting (PONV)
are frequent and distressing complications after
neurosurgical procedures (1). The reported incidence
of PONV after elective craniotomy has been found to
be between 44% and 70% in different studies (2–5).
Vomiting may increase intracranial and/or cerebral
intravascular pressure, jeopardizing hemostasis and
cerebral perfusion, and may cause an electrolyte
imbalance like hyponatremia (5,6).
The area postrema of the brain stem, which is
where the chemoreceptor trigger zone is located,
is rich in dopamine, opioid, and serotonin (or
5-hydroxytryptamine; 5-HT3) receptors (7–9).
These receptors may play an important role in the
transmission of impulses to the emetic center (10).

The new generation of antiemetic agents, called 5-HT3
receptor antagonists (ondansetron, granisetron,
ramosetron, and dolasetron), are superior to
conventional antiemetics for the prevention and
treatment of PONV (11). Palonosetron, a secondgeneration 5-HT3 receptor antagonist, has provided
better PONV results, has higher receptor affinity, and
has a much longer half-life (approximately 40 h) than
other 5-HT3 receptor antagonists (12). However,
there are no reports about the efficacy of different
doses of palonosetron in elective craniotomy for
supratentorial tumor resection. This prospective,
randomized, double-blinded study was designed to
evaluate the efficacy and safety of different doses of
palonosetron for the prevention of postoperative
nausea and vomiting in patients undergoing
supratentorial craniotomy.
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Materials and methods
After approval by the ethics committee, we obtained
written informed consent from 90 American Society
of Anesthesiologists (ASA) status I–III patients aged
between 18 and 76 years old who were scheduled for
elective supratentorial craniotomy for resection of
mass lesions. The patients were randomly assigned
into 3 groups to be administered 0.05 mg palonosetron
(group P1), 0.075 mg palonosetron (group P2), or
saline (group S) in a double-blinded fashion. The
exclusion criteria were a history of vomiting such
as motion sickness, antiemetic use preoperatively,
allergy to palonosetron, pregnancy, breast-feeding,
morbid obesity, cardiac dysrhythmia, clinical
symptoms (hypertension, bradycardia, nausea–
vomiting, confusion, and papilledema), radiological
images due to increased intracranial pressure,
mental retardation, or psychiatric illness. All patients
in the 3 groups received corticosteroid therapy
(dexamethasone: 4 mg/6 h) during the preoperative
and postoperative periods. Patients were monitored
with electrocardiography and for heart rate,
noninvasive blood pressure, pulse oximetry, airway
gas levels, and end-tidal CO2 concentration using a
Datex–Engstrom AS/3 monitor (Datex–Engstrom,
Helsinki, Finland). Saline was given to all patients at
an hourly rate of 5 mL/kg during the study period.
Anesthesia was induced with 2–2.5 mg/kg propofol
(13) and 2 µg/kg fentanyl. Endotracheal intubation
was facilitated by 0.1 mg/kg vecuronium. After
orotracheal intubation with an armored tube resistant
to kinking, general anesthesia was maintained with 1
MAC sevoflurane in a 50% air and oxygen mixture
and intermittent bolus doses of 1 µg/kg fentanyl. At
the end of the operation, residual neuromuscular
blockade was antagonized with intravenous atropine
(0.015 mg/kg) and neostigmine (0.04 mg/kg). The
patient was extubated after adequate spontaneous
ventilation and movement.
The patients in group P1 (n = 30) received 0.05 mg
of palonosetron (Aloxi, 250 µg/5 mL, Helsinn Birex
Pharmaceuticals Ltd., Dublin, Ireland) diluted to 5
mL with 0.9% saline (1 mL palonosetron, 4 mL 0.9%
saline), the patients in group P2 (n = 30) received
0.075 mg of palonosetron diluted to 5 mL with 0.9%
saline (1.5 mL palonosetron, 3.5 mL 0.9% saline), and
the patients in group S (n = 30) received 5 mL of 0.9%
saline. The drugs were prepared and administered
1242

by anesthesia staff not involved in collecting the
data. The drugs were given intravenously at the
commencement of dural closure.
Postoperatively, the patients were transferred to
the neurosurgical intensive care unit, and trained
nursing staff recorded each episode of nausea and
vomiting that occurred for 72 h. Although the nurses
were aware of the nature of the study, they were
blinded to the drug administered. Patient age, weight,
and height; the duration of surgery; anesthesia; and
intraoperative narcotic consumption were recorded.
Episodes of nausea and vomiting and requests (plus
time of request) for rescue antiemetic medication were
recorded at 0 min and 6, 24, 48, and 72 h. Nausea was
defined as a feeling of the urge to vomit as solicited by
the investigators during assessments. Vomiting was
defined as expulsion of stomach contents through
the mouth. Retching was defined as an attempt to
vomit that was not productive of stomach contents.
An emetic episode was defined as a single vomit or
retch or any number of continuous vomits or retches.
Metoclopramide (10 mg) was given intravenously to
the patients as a rescue antiemetic after more than 2
episodes of emesis within 30 min or persistent nausea
lasting more than 10 min. All patients received 1 g
of paracetamol (Perfalgan, Bristol-Myers Squibb
Pharmaceuticals Ltd., New York, USA) intravenously
every 8 h for postoperative pain management.
The primary outcome evaluated in this study
was the efficacy (and safety) of using different doses
of palonosetron to prevent postoperative nausea
and vomiting in patients undergoing supratentorial
surgery.
Statistical analyses were performed using SPSS
(version 15.0, SPSS Inc., Chicago, IL, USA) software.
The Kolmogorov–Smirnov test was used to assess the
normal distribution of the data. One-way ANOVA
was used to compare differences between the groups
for parametric data with normal distribution.
Statistical significance was determined by the Scheffe
test, which is a post hoc multiple comparison test.
Differences between measurements carried out before
and after the drug administration or procedure were
compared with paired t-tests. Pearson’s chi-square
test was used to compare the differences between
groups for categorical variables. A P-value less than
0.05 was accepted as statistically significant.
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Results
There was no intergroup difference with regard to
age, height, weight, sex, or ASA classification of the
cases (P > 0.05) (Table 1).
The mean duration of surgery was 172.3 min in
the control group, whereas it was 199 and 182 min
in the 0.05 mg and 0.075 mg palonosetron groups,
respectively. There was no statistically significant
difference between the groups with regard to duration
of surgery (P = 0.216) (Table 1).
The mean intraoperative fentanyl consumption
was 246 µg in the control group, whereas it was 275 µg
and 248 µg in the 0.05 mg and 0.075 mg palonosetron

groups, respectively. There was no statistically
significant difference between the groups with regard
to mean intraoperative fentanyl consumption (P =
0.248) (Table 1).
Intergroup comparisons showed no difference
with regard to mean blood pressure or heart rate (P >
0.05) (Tables 2 and 3).
Although group P2 demonstrated statistically
significantly lower nausea rates at 0–6 h compared
with group P1 and the control group (P < 0.043),
no intergroup difference was observed at 6–24 or 24
–72 h (P > 0.05) (Table 4). There was no statistically
significant difference between the groups in terms of

Table 1. Demographic and clinical data.
Group S
(n = 30)
(mean ± SD)

Group P1
(n = 30)
(mean ± SD)

Group P2
(n = 30)
(mean ± SD)

P

Age (years)

49.8 ± 10.4

49.3 ± 14.1

47.8 ± 14.5

0.820

Weight (kg)

75.9 ± 11.6

72.7 ± 10.8

72.4 ± 13.3

0.450

Height (cm)

164.8 ± 88

166.3 ± 7.8
15/15

166.8 ± 7.8
14/16

0.620

18/9/3

16/14/0

172.3 ± 47.6

199 ± 64.8

182 ± 63.5

0.216

246 ± 64

275 ± 87

248 ± 64

0.248

Sex (M/F)

17/13
10/17/3

No. of patients with ASA physical status (I/II/III)
Duration of surgery (min)
Total intraoperative fentanyl (µg)

0.733
0.099

P < 0.05 indicates statistical significance. S = control group, P1 = 0.05 mg palonosetron, P2 = 0.075 mg palonosetron.
Table 2. Mean blood pressure (mmHg).
Group S
(n = 30)
(mean ± SD)

Group P1
(n = 30)
(mean ± SD)

Group P2
(n = 30)
(mean ± SD)

P

MBP before induction

108.7 ± 17.3

101.1 ± 14.0

100.3 ± 13.8

0.067

MBP before intubation

85.0 ± 15.2

79.5 ± 12.2

82.7 ± 19.0

0.401

MBP after intubation

112.0 ± 20.9

104.1 ± 18.1

109.5 ± 19.3

0.283

MBP before medication

90.8 ± 12.5

92.3 ± 15.8

90.2 ± 10.7

0.815

MBP after medication

90.7 ± 14.6

90.7 ± 16.9

89.6 ± 12.4

0.947

MBP before extubation

110.8 ± 16.8

109.7 ± 19.4

110.5 ± 15.4

0.938

MBP 30 min after extubation

104.4 ± 23.5

98.9 ± 10.9

100.7 ± 16.6

0.335

MBP: Mean blood pressure. P < 0.05 indicates statistical significance. S = control group, P1 = 0.05 mg palonosetron, P2
= 0.075 mg palonosetron.
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Table 3. Heart rate (beats/min).
Group S
(n = 30)
(mean ± SD)

Group P1
(n = 30)
(mean ± SD)

Group P2
(n = 30)
(mean ± SD)

P

HR before induction

83.2 ± 15.2

77.9 ± 12.5

83.0 ± 20.1

0.364

HR before intubation

79.1 ± 15.3

72.7 ± 10.5

74.1 ± 15.6

0.186

HR after intubation

86.7 ± 14.8

83.3 ± 13.8

84.6 ± 17.5

0.689

HR before medication

76.7 ± 10.5

71.8 ± 10.0

73.9 ± 12.6

0.234

HR after medication

76.0 ± 14.4

72 .6 ± 12.3

75.1 ± 13.1

0.599

HR before extubation

95.0 ± 19.2

88.0 ± 14.5

91.1 ± 14.5

0.253

HR 30 min after extubation

87.4 ± 11.0

83.2 ± 12.4

84.3 ± 12.1

0.368

HR: Heart rate. P < 0.05 indicates statistical significance. S = control group, P1 = 0.05 mg palonosetron, P2 = 0.075 mg
palonosetron.
Table 4. Postoperative retching, nausea, and vomiting.
Group S
(n = 30)
n (%)

Group P1
(n = 30)
n (%)

0–6 h:
Retching
Nausea
Vomiting

9 (30)
14 (46.7)
9 (30)

5 (16.7)
11 (36.7)
9 (30)

3 (10)
5 (16.7)*
3 (10)

0.131
0.043
0.107

6–24 h:
Retching
Nausea
Vomiting

5 (16.7)
5 (16.7)
4 (13.3)

3 (10)
4 (12.3)
4 (12.3)

2 (6.7)
2 (6.7)
2 (6.7)

0.455
0.484
0.638

24–72 h:
Retching
Nausea
Vomiting

4 (13.3)
5 (16.7)
2 (6.7)

3 (10)
3 (10)
3 (10)

0 (0)
0 (0)
0 (0)

0.133
0.074
0.227

17 (56.7)

12 (40)

0–72 h: Retching, nausea, or vomiting

Group P2
(n = 30)
n (%)

5 (16.7)*

P

0.006

P < 0.05 indicates statistical significance. S = control group, P1 = 0.05 mg palonosetron, P2 = 0.075 mg palonosetron.
*Significantly reduced relative to control group (P < 0.05).

vomiting or retching at 0–6, 6–24, or 24–72 h (P >
0.05) (Tables 4). However, the incidence of retching,
nausea, or vomiting was significantly lower in the
0.075 mg palonosetron group than in the control
group (P = 0.003). There was no statistically significant
difference between the 0.05 mg palonosetron and
control group (P = 0.301) (Table 4).
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Discussion
In this study, 0.075 mg of palonosetron was observed
to reduce the incidence of nausea within the first
6 h postoperatively. Kathirvel et al. (14) found
the incidence of nausea–vomiting among elective
craniotomy cases at 24 h postoperatively to be 44%,
whereas it was 24% in patients treated with 4 mg of
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ondansetron. The need for an antiemetic was reported
to decrease from 15% to 5%. Fabling et al. (3) conducted
a retrospective study of 199 adult cases with a history
of elective craniotomy, among which the incidence of
nausea at 48 h was 50% and the incidence of vomiting
at 48 h was 39%. Postoperatively, 61% of the cases
required an antiemetic (used intraoperatively in
7%). However, infratentorial craniotomy, female sex,
and young age have been reported to be important
risk factors for this complication. Madenoglu et
al. (15) maintained anesthesia with isoflurane and
nitrous oxide in oxygen in their earlier supratentorial
craniotomy procedures, and they reported the
incidence of nausea and vomiting as 46.7% and 56.%,
respectively, while noting a drop in these values down
to 30% and 26.7%, respectively, due to delivery of 2
mg of tropisetron.
In the present study, anesthesia was maintained
with sevoflurane and an oxygen–air mixture. Known
emetic potentials of opioids probably did not affect
the rate of nausea and vomiting between the 3
groups because there was no statistically significant
difference between the groups with regard to mean
intraoperative fentanyl consumption.
In the current study, only nausea presented a
statistically significant decline at 0–6 h in the 0.075
mg palonosetron group. The incidences of retching,
nausea, or vomiting were 56% in the control group,
40% in the 0.05 mg palonosetron group, and 16.7%
in the 0.075 mg palonosetron group at 0–72 h
postoperatively. These incidences were lower in
the 0.075 mg palonosetron group than in the other
groups, which suggests that palonosetron is more
effective at reducing PONV when used at 0.075 mg
compared to 0.05 mg.
White et al. (16) compared the effect on PONV
of 0.1–30 µg/kg palonosetron versus a placebo in
381 patients who underwent major gynecological
surgery, and they found that palonosetron at doses
of ≥1 µg/kg successfully decreased the incidence of
nausea 0–24 h postoperatively.
Kovac et al. (17) conducted a study on 544
patients with a history of gynecological or breast
surgery. They delivered 0.025, 0.050, and 0.075 mg
doses of palonosetron for PONV prophylaxis, and
0.075 mg palonosetron was found to be significantly
more effective than a placebo at preventing nausea

and vomiting at both early (0–24 h) and late (24–72
h) postoperative periods.
Candiotti et al. (18) assessed the prophylactic effect
of palonosetron at doses of 0.025, 0.050, and 0.075
mg in 574 patients who underwent laparoscopic day
surgery, and the total incidence at 0–72 h of retching,
nausea, and vomiting and early vomiting and the
severity of nausea were found to be lower in the 0.075
mg palonosetron group than in the placebo group.
In our study, similarly to the above-mentioned
studies, 0.075 mg of palonosetron reduced nausea
episodes at 0–6 h and decreased the incidence
of nausea and vomiting at other times. We
observed no significant change in hemodynamics
following delivery of the drug. None of the patients
demonstrated postoperative side effects (such as
constipation or bradycardia) due to palonosetron.
Based on this study, we can recommend palonosetron
as a safe agent with regard to hemodynamics and
postoperative side effects at the aforementioned
doses. In the present study, 51.1% of the patients were
female and 48.9% were male. There was no statistically
significant difference between the groups in terms
of sex or age. Similarly, analgesic consumption and
duration of surgery were almost the same in the
groups in our study.
Due to the increasing cost of treatment for PONV,
cost-effectiveness continues to be a major concern
when choosing therapeutic agents. However, there
is a large cost difference between palonosetron and
other 5-HT3 receptor antagonists. With respect to
palonosetron, it is difficult to decide how much
extra cost the added benefit is worth. A limitation
of this study is that sample size calculation was not
performed.
In conclusion, we suggest that intraoperative
palonosetron is more effective at 0.075 mg than at
0.05 mg; therefore, it would be more appropriate to
use palonosetron at 0.075 mg for the prevention of
PONV in supratentorial craniotomy cases.
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